エルロチニブ塩酸塩 (TARCEVA)

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H413：長期的影響により水生生物に有害のおそれ

• 注意書き

  P273：環境への放出を避けること。

  P501：内容物/容器を．．．に廃棄すること。

エルロチニブ塩酸塩 (TARCEVA) 価格

エルロチニブ塩酸塩 (TARCEVA) 化学特性,用途語,生産方法

• 外観

  白色～うすい褐色、結晶性粉末～粉末

• 溶解性

  ジメチルスルホキシドに溶け、アセトン及び水にほとんど溶けない。

• 用途

  上皮成長因子受容体（EGFR） チロシンキナーゼの阻害剤です。EGFR 遺伝 子変異による、腫瘍細胞の増殖を抑制する作 用を示します。

• 効能

  抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬

• 商品名

  タルセバ (中外製薬); タルセバ (中外製薬)

• 化学的特性

  Off-White Solid

• 使用

  Erlotinib hydrochloride (V), a quinazoline derived small molecule inhibitor of epidermal growth factor receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide.

• 定義

  ChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.

• 一般的な説明

  Erlotinib is available as 25-, 100-, and 150-mg tablets fororal administration and is used after failure of first-linetherapy in metastatic NSCLC and as first-line therapy incombination with gemcitabine in the treatment of metastaticpancreatic cancer, and in treating malignant gliomas.The structural similarity to gefitnib imparts similar pharmacokineticbehavior with bioavailability of 60% and proteinbinding of 93%. The agent is extensively metabolizedprimarily by CYP3A4. Three major metabolic pathwayshave been identified, involving oxidative-O-demethylationof the side chains followed by further oxidation to give thecarboxlic acids, oxidation of the acetylene functionalityto give a carboxylic acid, and aromatic hydroxylation ofthe phenyl ring para to the electron-donating nitrogen. Themetabolites are primarily eliminated in the feces, and theterminal half-life is 36 hours.The major toxicities seenwith the agent are dose-limiting skin rash and diarrhea.Other common adverse effects include shortness of breath,fatigue, and nausea.

エルロチニブ塩酸塩 (TARCEVA) 上流と下流の製品情報

エルロチニブ塩酸塩 (TARCEVA) 生産企業

Global(762)Suppliers

エルロチニブ塩酸塩 (TARCEVA) スペクトルデータ(¹HNMR)

183319-69-9, エルロチニブ塩酸塩 (TARCEVA) キーワード